Top Story

Keith C. Ferdinand, MD, highlights recent data on link between CVDs, diabetes drugs

October 30, 2014

BOSTON — At the Cardiometabolic Health Congress, Keith C. Ferdinand, MD, FACC, professor of clinical medicine at Tulane University School of Medicine in New Orleans, outlines recent trial data and FDA updates related to CV and diabetes care.

During a session, Ferdinand discussed a trial that assessed the impact of the GLP-1 agonist dulaglutide on BP and heart rate in a cohort of 755 patients. Ferdinand, who was the principal investigator for the trial, noted a small increase in heart rate with dulaglutide 1.5 mg compared with placebo, but similar results between placebo and dulaglutide 0.75 mg. Patients who received the 1.5 mg dose also exhibited a significant decrease in BP during a 24-hour period. He noted that, while the trial did not assess CV outcomes, results suggest that GLP-1 agonists may aid in BP control, although long-term outcome trials should be performed to determine whether the observed heart rate increase is potentially problematic.

figure Meeting News CoverageVideo

Francesco Rubino, MD: 'Converting' bariatric surgery into a diabetes intervention poses challenges

October 24, 2014
BOSTON — Converting a procedure that has been used for years as a weight-loss intervention into a treatment aimed primarily at diabetes or metabolic disease poses…
figure Meeting News Coverage

Cardiometabolic Health Congress highlights latest research on CVD, diabetes, obesity

October 23, 2014
BOSTON — The latest innovative research in diabetes, hypertension, lipids, obesity and thrombosis was analyzed by experts at the Cardiometabolic Health…
In the Journals

Atherosclerosis risk increased among men with diabetes, low testosterone

October 17, 2014
A greater risk for developing atherosclerosis is found among middle-aged men with low testosterone and type 2 diabetes, according to recent study findings published in…
CME
figure

Lipid Forum II Highlights

This activity is supported by an educational grant from Genentech.

Risk stratification and appropriate therapies for various dyslipidemias remain difficult concepts for practitioners…
More »
Meeting News Coverage Video
figure

Keith C. Ferdinand, MD, highlights recent data on link between CVDs, diabetes drugs

October 30, 2014
BOSTON — At the Cardiometabolic Health Congress, Keith C. Ferdinand, MD, FACC, professor of clinical medicine at…
More »
CME
figure

Practical Lipidology: 2013

This activity is supported by an educational grant from Genentech.

The rise in the prevalence of obesity in the last few decades and its growing impact on health has driven the…
More »

Filter By:

Nutrition education lacking in medical training

August 26, 2014
A group of physicians are questioning how well doctors can provide nutrition information and counseling to patients, particularly those with CVD…

AHA and ADA: CV risk assessment, monitoring essential for patients with type 1 diabetes

August 21, 2014
A greater understanding of the pathophysiology, risk prediction and treatment of CVD in patients with type 1 diabetes is essential to minimize the…
figure FDA News

FDA opens dialogue on interim results of CV safety in diabetes drug trials

August 12, 2014
The FDA has launched a dialogue on how to handle confidentiality of the interim results for cardiovascular outcomes in diabetes treatment trials…
In the Journals

Knowing modifiable risk factors may reduce CV death in type 2 diabetes

July 9, 2014
Determining vascular calcification and modifiable risk factors for heart disease could provide patients with type 2 diabetes the insight needed to…
Meeting News Coverage

Higher obesity increases odds for cardiovascular, cancer, diabetes deaths

July 8, 2014
Adults with class III obesity are more likely to die from all causes than those within normal weight range, but particularly from heart disease…
In the Journals Perspective

'Bundled' management reduced diabetes-related vascular complications

July 3, 2014
A team-based model with an all-or-none or “bundled” approach to primary care reduced the risk for myocardial infarction, stroke and…
In the Journals

Sitagliptin may increase hospitalizations in patients with diabetes, HF

July 2, 2014
Recent study results found that sitagliptin use by patients with type 2 diabetes and HF may increase the risk for HF-related…
In the Journals

CV risk control differs by sex for patients with type 2 diabetes

July 2, 2014
Composite control of cardiovascular risk factors varies by sex for patients with type 2 diabetes, with women’s significantly lower than…
Meeting News Coverage

RYGB adds CV, quality-of-life benefits for obesity, type 2 diabetes

July 1, 2014
CHICAGO — Roux-en-Y gastric bypass surgery could bring additional benefits for some patients with obesity and type 2 diabetes, according to…
In the Journals

Homeless men boosted health playing pick-up soccer

June 29, 2014
As World Cup competition continues, a timely study published in the Scandinavian Journal of Medicine & Science in Sports showed that playing…
More Headlines »